SNTVERSE
Research SNTVERSE (SVE.WA) on Bullrun: market cap PLN 214.37M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSVE.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 214.37M
- Financial periodQ1 2026
- RevenuePLN 13.61M
- Net income-PLN 3.61M
- Free cash flowPLN 4.66M
- Gross margin52.7%
Valuation Snapshot
latest market cap is PLN 214.37M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | PLN 42.01M | -PLN 19.93M | -PLN 16.20M | 56.1% | n/a | PLN 1.67M | PLN 84.65M | PLN 124.68M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-11 | PLN 214.37M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About SNTVERSE
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SNTVERSE's market cap?
SNTVERSE's market capitalization is PLN 214.37M.
What does SNTVERSE do?
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments.